Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton, Dickinson and Company (BDX) insider files a Form 144 to sell a small block of shares under an existing trading plan. The notice covers a proposed sale of 75 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 01/26/2026. The filing states an aggregate market value of 15134.25 for these 75 shares, compared with 285418551 shares of common stock outstanding.
The securities to be sold were acquired as restricted stock units from the issuer on 08/20/2025, in an amount of 75 shares. The form also lists prior Rule 10b5-1 sales for Michael Feld over the past three months, including 74, 75, and 57 common shares sold on 12/26/2025, 12/01/2025, and 10/27/2025, respectively, with disclosed gross proceeds for each transaction.
Becton, Dickinson and Company senior vice president, controller and chief accounting officer Pamela L. Spikner reported a routine share withholding related to equity compensation. On January 21, 2026, 84 shares of common stock were withheld at a price of $0.00 per share to cover withholding taxes tied to the vesting of previously granted restricted stock units. After this tax-withholding transaction, Spikner directly beneficially owned 1,832 shares of Becton Dickinson common stock.
Becton Dickinson & Co executive Michael David Garrison reported multiple stock transactions. On 01/15/2026, he exercised 3,054 stock appreciation rights at an exercise price of $167.91 per share, receiving 3,054 shares of common stock. He then disposed of 2,454 shares at $209 per share and sold 600 additional shares at $209 and 1,010 shares at $206.54.
After these transactions, he directly owned 12,095 shares of Becton Dickinson common stock. The filing notes that the reported transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
An insider of BDX has filed a notice of proposed sale of 1,610 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $333,946.20, to be sold on or about 01/15/2026 on the NYSE. The shares were acquired from the issuer via 1,010 performance stock units on 11/26/2025 and the cash exercise of 600 stock options on 01/15/2026. Shares outstanding are listed as 285,418,551. During the prior three months, a Rule 10b5-1 plan for Michael Garrison sold 629 common shares for gross proceeds of $123,302.87.
Becton, Dickinson and Company (BD) reports that its BD 401(k) Plan will experience a temporary blackout period for the BD Common Stock Fund in connection with a pending transaction with Waters Corporation. The blackout is being implemented so the Plan can add Waters Common Stock Fund interests to participant accounts. It will begin after the market closes on the closing date of the Waters transaction and is expected to end during the week following that closing date.
During the blackout, Plan participants will not be able to carry out transactions involving the BD Common Stock Fund, including exchanges into or out of the fund, loans or partial withdrawals from amounts invested in the fund, or final distributions if any portion of their accounts is invested in the fund. BD shareholders and other interested parties can obtain the actual beginning and ending dates of the blackout period and related information at no charge by contacting Fidelity at the phone number provided.
Becton Dickinson & Co. executive vice president and Chief ISC Officer David Shan reported a routine share withholding related to equity compensation. On 01/03/2026, 44 shares of Becton Dickinson common stock were withheld at a price of $0 to cover taxes due on the vesting of previously reported restricted stock unit awards. After this transaction, Shan beneficially owns 8,926 shares of common stock in direct ownership.
Becton, Dickinson and Company insider plans small stock sale under Rule 144. A person identified as Michael Feld has filed a notice to sell 74 shares of the company’s common stock through a broker on the NYSE, with an aggregate market value of approximately $14,512.88. The shares come from restricted stock units acquired on 08/20/2025.
The filing also lists prior sales over the past three months under a Rule 10b5-1 trading plan, including 75 shares sold on 12/01/2025 for gross proceeds of $14,502.00 and 57 shares sold on 10/27/2025 for gross proceeds of $10,602.57. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.
Becton, Dickinson and Company is asking shareholders to vote at its virtual 2026 annual meeting on four items: electing 13 directors, ratifying Ernst & Young as independent auditor, approving named executive officer pay on an advisory basis, and increasing the shares available under its 2004 equity-based compensation plan by 3,935,000 shares.
The materials highlight record fiscal 2025 revenue of $21.8 billion, GAAP EPS of $5.82 and record adjusted diluted EPS of $14.40, supported by margin expansion from its BD Excellence program. BD returned $2.2 billion to shareholders through buybacks and dividends and marked its 54th consecutive annual dividend increase.
BD also describes the planned Reverse Morris Trust transaction combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, which is expected to generate about $4 billion in cash for BD and give its shareholders roughly 39% ownership of the new life sciences company, alongside extensive detail on governance, sustainability goals and risk oversight.